COSCIENS Biopharma (CSCI) Competitors $3.44 -0.33 (-8.73%) Closing price 03:56 PM EasternExtended Trading$3.44 0.00 (-0.03%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CSCI vs. SNTI, GANX, PRLD, EGRX, ELYM, PEPG, JSPR, RNXT, XCUR, and NBRVShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Senti Biosciences (SNTI), Gain Therapeutics (GANX), Prelude Therapeutics (PRLD), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), PepGen (PEPG), Jasper Therapeutics (JSPR), RenovoRx (RNXT), Exicure (XCUR), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry. COSCIENS Biopharma vs. Its Competitors Senti Biosciences Gain Therapeutics Prelude Therapeutics Eagle Pharmaceuticals Eliem Therapeutics PepGen Jasper Therapeutics RenovoRx Exicure Nabriva Therapeutics COSCIENS Biopharma (NASDAQ:CSCI) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Which has stronger earnings and valuation, CSCI or SNTI? COSCIENS Biopharma has higher revenue and earnings than Senti Biosciences. COSCIENS Biopharma is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOSCIENS Biopharma$9.59M1.13-$15.31M-$5.80-0.59Senti Biosciences$2.56M15.69-$52.79M-$10.84-0.14 Is CSCI or SNTI more profitable? Senti Biosciences has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -194.50%. COSCIENS Biopharma's return on equity of -101.01% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets COSCIENS Biopharma-194.50% -101.01% -43.90% Senti Biosciences N/A -177.24%-67.38% Do insiders & institutionals have more ownership in CSCI or SNTI? 0.7% of COSCIENS Biopharma shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 0.1% of COSCIENS Biopharma shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, CSCI or SNTI? COSCIENS Biopharma has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Do analysts recommend CSCI or SNTI? Senti Biosciences has a consensus price target of $8.50, suggesting a potential upside of 451.95%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CSCI or SNTI? In the previous week, Senti Biosciences had 3 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 3 mentions for Senti Biosciences and 0 mentions for COSCIENS Biopharma. Senti Biosciences' average media sentiment score of 1.00 beat COSCIENS Biopharma's score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media. Company Overall Sentiment COSCIENS Biopharma Neutral Senti Biosciences Positive SummarySenti Biosciences beats COSCIENS Biopharma on 11 of the 16 factors compared between the two stocks. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.84M$2.94B$5.42B$9.58BDividend YieldN/A2.41%4.31%4.17%P/E Ratio-0.5916.5729.5723.97Price / Sales1.13269.64424.34186.76Price / CashN/A42.1735.8458.51Price / Book0.997.747.995.54Net Income-$15.31M-$54.43M$3.26B$265.48M7 Day Performance-11.99%-0.91%-0.09%-0.41%1 Month Performance0.03%8.53%4.19%1.39%1 Year PerformanceN/A13.40%29.38%24.69% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$3.44-8.7%N/AN/A$10.84M$9.59M-0.5920Upcoming EarningsGap UpSNTISenti Biosciences2.5541 of 5 stars$1.80-3.7%$8.50+372.2%+1.2%$48.77MN/A-0.174Positive NewsEarnings ReportGANXGain Therapeutics3.1195 of 5 stars$1.57-3.1%$8.20+422.3%+54.5%$48.71M$50K-1.8320News CoveragePRLDPrelude Therapeutics3.3191 of 5 stars$0.83-2.4%$4.50+441.1%-84.8%$48.11M$7M-0.49120Upcoming EarningsGap UpHigh Trading VolumeEGRXEagle Pharmaceuticals1.9892 of 5 stars$3.69flatN/A-29.6%$47.92M$257.55M0.00100ELYMEliem TherapeuticsN/A$1.60+10.3%N/A-76.3%$47.60MN/A-3.029Gap UpPEPGPepGen2.6967 of 5 stars$1.38-3.5%$7.67+455.6%-85.4%$46.79MN/A-0.4430Earnings ReportUpcoming EarningsJSPRJasper Therapeutics2.578 of 5 stars$2.95-4.8%$29.75+908.5%-82.6%$46.57MN/A-0.5620Upcoming EarningsRNXTRenovoRx2.5206 of 5 stars$1.22-2.4%$7.25+494.3%+5.3%$45.72M$40K-3.056News CoverageUpcoming EarningsXCURExicure0.8963 of 5 stars$6.63-8.2%N/A+1,108.2%$45.61M$500K-1.7450Upcoming EarningsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies SNTI Competitors GANX Competitors PRLD Competitors EGRX Competitors ELYM Competitors PEPG Competitors JSPR Competitors RNXT Competitors XCUR Competitors NBRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSCI) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSCI Stock Alerts